MediWound Announces Peer-Reviewed Publication Of EscharEx Mechanism Of Action Study Assessing Its Effects On Biofilm And Microbial Loads
December 21, 9:13 AM
MediWound Ltd. (NASDAQ:MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled "An Open-label, Proof of Concept Study,
Natera Announces New Study Highlighting The Benefits Of Signatera’s Unique Method Of Quantifying ctDNA
December 21, 9:10 AM
Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higherNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing,
Equillium Announces Update On Multi-Cytokine Inhibitors EQ101 & EQ102 In Development For Alopecia Areata And Celiac Disease
December 21, 9:09 AM
EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024EQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of further clinical
Vaxart Announces Last Subject Dosed In Phase 1 Trial Of Its Norovirus Vaccine Candidate In Lactating Mothers
December 21, 9:04 AM
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced that it has completed enrollment and dosing in the Phase 1
Calliditas Therapeutics AB Announced That The FDA Approved TARPEYO Delayed Release Capsules To Reduce The Loss Of Kidney Function In Adults With Primary Immunoglobulin A Nephropathy At Risk For Disease Progression
December 20, 5:35 PM
TARPEYO (investigational name NEFECON) is the only FDA-approved treatment for IgAN to significantly reduce the loss of kidney function. TARPEYO is now
ResMed Notifies Customers About Updated Instructions And Labeling For Masks With Magnets Due To Potential Interference With Certain Medical Devices
December 20, 5:09 PM
ResMed (NYSE:RMD, ASX: RMD)))) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants
Dermata Enrolls First Patient In Pivotal DMT310 Phase 3 STAR-1 Clinical Trial For Acne; About 550 Patients Will Be Treated Once Weekly For 12 Weeks
December 20, 5:09 PM
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20,
Fusion’s Pharma’s Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 3:17 PM
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis AG's (NYSE:
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA’s Panel Surprise Advisory Possibility: Analyst
December 20, 3:07 PM
Tuesday, Guardant Health Inc (NASDAQ: GH) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for its Shield blood test to screen for colorectal